<DOC>
	<DOC>NCT00577577</DOC>
	<brief_summary>To investigate the effects of rhIGF-I/rhIGFBP-3 treatment for 24 weeks on endurance, ambulation, cognitive functioning, insulin resistance, lipid levels, muscle function and strength, pain, gastrointestinal functioning, and quality of life endpoints in DM1 patients</brief_summary>
	<brief_title>Safety and Efficacy Study of Recombinant Human Insulin-Like Growth Factor-I/Recombinant Human Insulin-Like Growth Factor Binding Protein-3 (rhIGF-I/rhIGFBP-3) In Myotonic Dystrophy Type 1</brief_title>
	<detailed_description>Efficacy Measures: Endurance, Ambulation, Cognitive function, Insulin resistance, Cholesterol and triglycerides, Muscle function and strength, Pain, Gastrointestinal function, Quality of life MINIMUM INCLUSION CRITERIA 1. A diagnosis of DM1, confirmed by DM1 genetic mutation 2. Age 21 to 65 years (inclusive) 3. Ability to walk 30 feet - assistance with cane and/or leg bracing permitted 4. Able to self-administer study medication by subcutaneous injection or caregiver is available to administer study medication</detailed_description>
	<mesh_term>Myotonic Dystrophy</mesh_term>
	<mesh_term>Insulin, Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Mitogens</mesh_term>
	<criteria>Inclusion Criteria (list is not inclusive): A diagnosis of DM1, confirmed by DM1 genetic mutation Ability to walk 30 feet assistance with cane and/or leg bracing permitted Able to selfadminister study medication by subcutaneous injection or caregiver is available to administer study medication Exclusion Criteria (list is not inclusive): Congenital DM1 Weight greater than 100 kg or body mass index greater than 30 kg/m2 Prior treatment with glucocorticoids, anabolic steroids, testosterone, growth hormone, investigational agent within 60 days of screening Current diagnosis or history of malignancy expect for surgically cured skin cancer or pilomatricoma Changes in lipid lowering medications during the 3 months prior to screening Diaphragmatic weakness such that patients are unable to tolerate the supine position, or swallowing impairment such that patients are unable to maintain nutrition without use of gastrostomy. Major psychiatric illness (major depression, bipolar disorder or schizophrenia) within twelve months of screening History of noncompliance with other therapies</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2008</verification_date>
</DOC>